115 related articles for article (PubMed ID: 2512467)
1. Effects of gonadotrophin-releasing hormone agonist on uterine fibroids and bone density.
Bianchi G; Costantini S; Anserini P; Rovetta G; Monteforte P; Menada MV; Fagà L; De Cecco L
Maturitas; 1989 Sep; 11(3):179-85. PubMed ID: 2512467
[TBL] [Abstract][Full Text] [Related]
2. Long-term follow-up of patients with uterine fibroids after treatment with the LHRH agonist buserelin.
Matta WH; Shaw RW; Nye M
Br J Obstet Gynaecol; 1989 Feb; 96(2):200-6. PubMed ID: 2495020
[TBL] [Abstract][Full Text] [Related]
3. Toward removing uterine fibroids without surgery: subcutaneous infusion of a luteinizing hormone-releasing hormone agonist commencing in the luteal phase.
Healy DL; Lawson SR; Abbott M; Baird DT; Fraser HM
J Clin Endocrinol Metab; 1986 Sep; 63(3):619-25. PubMed ID: 3090092
[TBL] [Abstract][Full Text] [Related]
4. Clinical predictors for buserelin acetate treatment of uterine fibroids: a prospective study of 40 women.
Vollenhoven BJ; Shekleton P; McDonald J; Healy DL
Fertil Steril; 1990 Dec; 54(6):1032-8. PubMed ID: 2123160
[TBL] [Abstract][Full Text] [Related]
5. [GnRH-analogs in the therapy of uterine myomatosis].
Wieacker P; Geisthövel F; Adelberger V; Breckwoldt M
Ther Umsch; 1990 Dec; 47(12):951-7. PubMed ID: 2151405
[TBL] [Abstract][Full Text] [Related]
6. Shrinkage of uterine fibroids during therapy with goserelin (Zoladex): a luteinizing hormone-releasing hormone agonist administered as a monthly subcutaneous depot.
West CP; Lumsden MA; Lawson S; Williamson J; Baird DT
Fertil Steril; 1987 Jul; 48(1):45-51. PubMed ID: 2954863
[TBL] [Abstract][Full Text] [Related]
7. Gonadotropin releasing hormone agonist therapy and its effect on bone mass.
Nencioni T; Penotti M; Barbieri-Carones M; Ortolani S; Trevisan C; Polvani F
Gynecol Endocrinol; 1991 Mar; 5(1):49-56. PubMed ID: 1910246
[TBL] [Abstract][Full Text] [Related]
8. The binding of steroids to myometrium and leiomyomata (fibroids) in women treated with the gonadotrophin-releasing hormone agonist Zoladex (ICI 118630).
Lumsden MA; West CP; Hawkins RA; Bramley TA; Rumgay L; Baird DT
J Endocrinol; 1989 May; 121(2):389-96. PubMed ID: 2526844
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of LHRH analogue action in uterine fibroids.
Shaw RW
Horm Res; 1989; 32 Suppl 1():150-3. PubMed ID: 2533145
[TBL] [Abstract][Full Text] [Related]
10. Shrinkage of uterine fibroids by preoperative LHRH analogue injection.
McClelland HR; Quinn AJ
Ulster Med J; 1992 Apr; 61(1):51-5. PubMed ID: 1535743
[TBL] [Abstract][Full Text] [Related]
11. Doppler assessment of uterine blood flow changes in patients with fibroids receiving the gonadotropin-releasing hormone agonist Buserelin.
Matta WH; Stabile I; Shaw RW; Campbell S
Fertil Steril; 1988 Jun; 49(6):1083-5. PubMed ID: 2967195
[TBL] [Abstract][Full Text] [Related]
12. The short-term use of luteinising hormone-releasing hormone analogues in uterine fibroids.
Van der Spuy ZM; Fieggan AG; Wood MJ; Pienaar CA
Horm Res; 1989; 32 Suppl 1():137-40. PubMed ID: 2533144
[TBL] [Abstract][Full Text] [Related]
13. Treatment of uterine leiomyomas in perimenopausal women with gonadotropin-releasing hormone agonists.
Nakamura Y; Yoshimura Y
Clin Obstet Gynecol; 1993 Sep; 36(3):660-7. PubMed ID: 8403612
[No Abstract] [Full Text] [Related]
14. Treatment of estrogen-dependent gynecological disorders with the gonadotropin releasing hormone agonist buserelin.
Biberoglu K; Gursoy R; Yildiz A
Gynecol Endocrinol; 1991 Jun; 5(2):109-22. PubMed ID: 1833953
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of leiomyomas with luteinizing hormone-releasing hormone agonist].
Nakamura Y; Yoshimura Y; Yamada H; Maruyama K; Nanno T; Ubukata Y; Ando M; Takahashi K; Suzuki M
Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec; 42(12):1620-6. PubMed ID: 2126024
[TBL] [Abstract][Full Text] [Related]
16. Uterine leiomyoma and LHRH agonist treatment. A preliminary report.
Rolland R; Franssen AM; Willemsen WN; Corbey RS
Prog Clin Biol Res; 1986; 225():313-20. PubMed ID: 3097670
[No Abstract] [Full Text] [Related]
17. Treatment of uterine leiomyomata with a luteinizing hormone-releasing hormone agonist: the possibility of nonsurgical management in selected perimenopausal women.
Nakamura Y; Yoshimura Y; Yamada H; Ubukata Y; Ando M; Suzuki M
Fertil Steril; 1991 May; 55(5):900-5. PubMed ID: 1902420
[TBL] [Abstract][Full Text] [Related]
18. Involvement of annexin V in the antiproliferative effect of GnRH agonist on cultured human uterine leiomyoma cells.
Yamamoto H; Sato H; Shibata S; Murata M; Fukuda J; Tanaka T
Mol Hum Reprod; 2001 Feb; 7(2):169-73. PubMed ID: 11160843
[TBL] [Abstract][Full Text] [Related]
19. Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
Maheux R; Lemay A; Blanchet P; Friede J; Pratt X
Hum Reprod; 1991 Apr; 6(4):500-5. PubMed ID: 1655823
[TBL] [Abstract][Full Text] [Related]
20. Total and unbound cytosolic estrogen and progesterone receptors in myometrium and fibroid after gonadotropin-releasing hormone agonist treatment.
Fernández-Montolí ME; Díez-Gibert O; Samaniego JM; Balagueró L; Navarro MA
Fertil Steril; 1995 Mar; 63(3):522-7. PubMed ID: 7851581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
